I MAB has a total of 80 patent applications. It decreased the IP activity by 22.0%. Its first patent ever was published in 2017. It filed its patents most often in Republic of Korea, WIPO (World Intellectual Property Organization) and China. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are R S R LTD, KIRA BIOTECH PTY LTD and ADAERATA LTD PARTNERSHIP.
# | Country | Total Patents | |
---|---|---|---|
#1 | Republic of Korea | 11 | |
#2 | WIPO (World Intellectual Property Organization) | 11 | |
#3 | China | 9 | |
#4 | United States | 9 | |
#5 | Canada | 6 | |
#6 | EPO (European Patent Office) | 5 | |
#7 | Israel | 5 | |
#8 | Brazil | 4 | |
#9 | Chile | 4 | |
#10 | Peru | 4 | |
#11 | Philippines | 4 | |
#12 | Singapore | 4 | |
#13 | Mexico | 3 | |
#14 | Colombia | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Medical preparations | |
#3 | Therapeutic chemical compounds | |
#4 | Analysing materials | |
#5 | Microorganisms |
# | Name | Total Patents |
---|---|---|
#1 | Fang Lei | 70 |
#2 | Guo Bingshi | 67 |
#3 | Wang Zhengyi | 67 |
#4 | Zang Jingwu | 63 |
#5 | Wang Yongqiang | 14 |
#6 | Jiang Wenqing | 10 |
#7 | Zhengyi Wang | 7 |
#8 | Jingwu Zang | 7 |
#9 | Bingshi Guo | 7 |
#10 | Lei Fang | 7 |
Publication | Filing date | Title |
---|---|---|
WO2020038397A1 | Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof | |
CN110678484A | anti-PD-L1/anti-LAG 3 bispecific antibodies and uses thereof | |
WO2019185029A1 | Anti-pd-l1 antibodies and uses thereof | |
CN110352200A | The antibody of the anti-T cell immunity receptor (TIGIT) with Ig and ITIM structural domain and its application | |
US2021095019A1 | Fusion Proteins Containing CD47 Antibodies and Cytokines | |
KR20190111894A | Anti-lag-3 antibodies and uses thereof | |
KR20190105122A | Anti-cd73 antibodies and uses thereof | |
BR112019008010A2 | isolated monoclonal antibody or immunologically active fragment thereof, isolated bispecific monoclonal antibody, pharmaceutical composition, method for treating a disease in a human subject in need thereof, fusion protein, cd47 gene encoded immunodominant epitope, and biological molecule | |
MX2018015584A | Anti-pd-l1 antibodies and uses thereof. | |
WO2018152687A1 | Anti-lymphocyte activation gene-3 (lag-3) antibodies and uses thereof |